FDA provides panel to evaluate diagnostic tests available for COVID-19

Effective Jun 1, 2020

Published Jun 1, 2020

Last Reviewed Jun 1, 2020

The U.S. Food and Drug Administration (FDA) is providing a SARS-COV-2 reference panel for the evaluation of diagnostic tests for COVID-19. The panels safeguard the quality of the tests and validation of new assay. They also test the calibration and monitoring of assay performance.

The FDA panel is available to commercial and laboratory developers who interact with the FDA through the pre-emergency use authorization (EUA) process.

Related link: For more information on the SARS-COV-2 reference panel, visit: https://bit.ly/3cjoWf0.

The information contained herein was current as of the publication date. © Copyright DecisionHealth, all rights reserved. Electronic or print redistribution without prior written permission of DecisionHealth is strictly prohibited by federal copyright law.